We are proud to announce that NaDeNo Nanoscience AS has been selected to join the AstraZeneca BioVentureHub, located at AstraZeneca’s R&D center in Gothenburg, Sweden.

The BioVentureHub is an invitation-only ecosystem designed to foster close collaboration between emerging life science companies and AstraZeneca’s scientific and development teams. As the second Norwegian company to join, NaDeNo’s entry follows the strategic Memorandum of Understanding signed in December 2023 between Oslo Cancer Cluster, Oslo Science City, and AstraZeneca BioVentureHub—aimed at accelerating Nordic life science innovation.

“We warmly welcome NaDeNo Nanoscience to the AstraZeneca BioVentureHub. Their integration into our ecosystem aligns perfectly with our commitment to drive innovation in the pharmaceutical landscape. We believe there is a great potential for synergies, and we can’t wait to see what we can achieve together,”
— Ulrika Edvardsson, Managing Director, AstraZeneca BioVentureHub

NaDeNo brings its proprietary PACA nanoparticle platform, designed for the efficient delivery of hydrophobic small-molecule drugs. Our one-step manufacturing process not only enables effective drug solubilization and encapsulation, but also allows for precise surface tailoring—opening the door for reviving potent drugs that have failed due to formulation limitations and for expanding the IP landscape of new drug candidates.

“The NaDeNo technology platform presents a promising methodology for improving the delivery of water-insoluble drugs. Their approach has the potential to overcome some limitations associated with conventional drug delivery systems, which often impede the effectiveness of therapeutics for patients.
Additionally, NaDeNo’s affiliation with the BioVentureHub facilitates valuable knowledge exchange to support the development and understanding of the technologies’ potential,”
— Susanna Abrahmsén-Alami, Senior Principal Scientist, AstraZeneca

As we begin this next chapter, we are energized by the opportunity to develop our PACA platform within a leading pharmaceutical environment—working alongside like-minded innovators and scientific pioneers.

“We are looking forward to being part of the BioVentureHub and are enthusiastic about the opportunities that lie ahead. It is inspiring to go forward, as we explore how our patented PACA Nanoparticle Platform can be developed within a big pharma context. We hope to contribute scientifically and become an integral part of the renowned BioVentureHub community and culture.”
— Annbjørg Falck, CEO and Co-founder, NaDeNo Nanoscience AS